|
1
|
Tan J, Wang Y, Gong X, Li J, Zhong W, Shan
L, Lei X, Zhang Q, Zhou Q, Zhao Y, et al: Antibiotic resistance in
neonates in China 2012-2019: A multicenter study. J Microbiol
Immunol Infect. 55:454–462. 2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang Q, Jin L, Sun S, Yin Y, Wang R, Chen
F, Wang X, Zhang Y, Hou J, Zhang Y, et al: Occurrence of high
levels of cefiderocol resistance in carbapenem-resistant
escherichia coli before its approval in China: A report from China
CRE-network. Microbiol Spectr. 10(e0267021)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jiang Y, Yang S, Deng S, Lu W, Huang Q and
Xia Y: Epidemiology and resistance mechanisms of tigecycline- and
carbapenem-resistant Enterobacter cloacae in Southwest
China: A 5-year retrospective study. J Glob Antimicrob Resist.
28:161–167. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
http://www.carss.cn/Report/Details?aId=862.
|
|
5
|
Bartal C, Rolston KVI and Nesher L:
Carbapenem-resistant Acinetobacter baumannii: Colonization,
infection and current treatment options. Infect Dis Ther.
11:683–694. 2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chen Y, Ji J, Ying C, Liu Z, Yang Q, Kong
H and Xiao Y: Blood Bacterial Resistant Investigation Collaborative
System (BRICS) Study Group. Blood bacterial resistant investigation
collaborative system (BRICS) report: A national surveillance in
China from 2014 to 2019. Antimicrob Resist Infect Control.
11(17)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jing N, Yan W, Zhang Q, Yuan Y, Wei X,
Zhao W, Guo S, Guo L, Gao Y, Zhao L, et al: Epidemiology and
genotypic characteristics of carbapenem resistant Enterobacterales
in Henan, China: A multicentre study. J Glob Antimicrob Resist.
29:68–73. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dimopoulos G, Almyroudi MP, Kapralos I,
Apostolopoulou O, Flevari A, Nicolau DP and Dokoumetzidis A:
Intrapulmonary pharmacokinetics of high doses of tigecycline in
patients with ventilator-associated pneumonia. Int J Antimicrob
Agents. 59(106487)2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yang T, Mei H, Wang J and Cai Y:
Therapeutic drug monitoring of tigecycline in 67 infected patients
and a population pharmacokinetics/microbiological evaluation of
A. baumannii study. Front Microbiol.
12(678165)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chang K, Wang H, Zhao J, Yang X, Wu B, Sun
W, Huang M, Cheng Z, Chen H, Song Y, et al: Polymyxin B/tigecycline
combination vs polymyxin B or tigecycline alone for the treatment
of hospital-acquired pneumonia caused by carbapenem-resistant
enterobacteriaceae or carbapenem-resistant Acinetobacter
baumannii. Front Med (Lausanne). 9(772372)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yaghoubi S, Zekiy AO, Krutova M, Gholami
M, Kouhsari E, Sholeh M, Ghafouri Z and Maleki F: Tigecycline
antibacterial activity, clinical effectiveness, and mechanisms and
epidemiology of resistance: narrative review. Eur J Clin Microbiol
Infect Dis. 41:1003–1022. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhou CY, Zhang L, Zhu N, Cai H, Chen G and
Luo Z: Dept.of Pharmacy, Anhui Provincial Children's Hospital,
Dept.of Pharmacy, the Fourth Affiliated Hospital of Anhui Medical
University. Specialized management and rationality analysis of
carbapenems and tigecycline in one hospital. Eval Anal Drug-Use
Hosp China. 20:989–995. 2020.
|
|
13
|
Bai XR, Jiang DC and Yan SY: High-dose
tigecycline in elderly patients with pneumonia due to
multidrug-resistant Acinetobacter baumannii in intensive
care unit. Infect Drug Resist. 13:1447–1454. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zha L, Pan L, Guo J, French N, Villanueva
EV and Tefsen B: Effectiveness and safety of high dose tigecycline
for the treatment of severe infections: A systematic review and
meta-analysis. Adv Ther. 37:1049–1064. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Xia G and Jiang R: Clinical study on the
safety and efficacy of high-dose tigecycline in the elderly
patients with multidrug-resistant bacterial infections: A
retrospective analysis. Medicine (Baltimore).
99(e19466)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chuang YC, Cheng CY, Sheng WH, Sun HY,
Wang JT, Chen YC and Chang SC: Effectiveness of tigecycline-based
versus colistin-based therapy for treatment of pneumonia caused by
multidrug-resistant Acinetobacter baumannii in a critical
setting: A matched cohort analysis. BMC Infect Dis.
14(102)2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhou Y, Chen X, Xu P, Zhu Y, Wang K, Xiang
D, Wang F and Banh HL: Clinical experience with tigecycline in the
treatment of hospital-acquired pneumonia caused by multidrug
resistant Acinetobacter baumannii. BMC Pharmacol Toxicol.
20(19)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Liu B, Li S, Li HT, Wang X, Tan HY, Liu S,
Pan PH, Li XG and Li XM: Outcomes and prognostic factors of
tigecycline treatment for hospital-acquired pneumonia involving
multidrug-resistant Acinetobacter baumannii. J Int Med Res.
48(300060520910917)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Huang F, Cao WX, Yan YY, Mao TT, Wang XW,
Huang D, Qiu YS, Lu WJ, Li DJ and Zhuang YG: Influence of
continuous renal replacement therapy on the plasma concentration of
tigecycline in patients with septic shock: A prospective
observational study. Front Pharmacol. 14(1118788)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Doi Y: Treatment options for
carbapenem-resistant gram-negative bacterial infections. Clin
Infect Dis. 69 (Suppl 7):S565–S575. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Bouza E: The role of new carbapenem
combinations in the treatment of multidrug-resistant gram-negative
infections. J Antimicrob Chemother. 76 (Suppl 4):iv38–iv45.
2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sheu CC, Chang YT, Lin SY, Chen YH and
Hsueh PR: Infections caused by carbapenem-resistant
enterobacteriaceae: An update on therapeutic options. Front
Microbiol. 10(80)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
De Pascale G, Lisi L, Ciotti GMP,
Vallecoccia MS, Cutuli SL, Cascarano L, Gelormini C, Bello G,
Montini L, Carelli S, et al: Pharmacokinetics of high-dose
tigecycline in critically ill patients with severe infections. Ann
Intensive Care. 10(94)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Xie J, Roberts JA, Alobaid AS, Roger C,
Wang Y, Yang Q, Sun J, Dong H, Wang X, Xing J, et al: Population
pharmacokinetics of tigecycline in critically ill patients with
severe infections. Antimicrob Agents Chemother. 61:e00345–17.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Xie J, Wang T, Sun J, Chen S, Cai J, Zhang
W, Dong H, Hu S, Zhang D, Wang X and Dong Y: Optimal tigecycline
dosage regimen is urgently needed: Results from a
pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte
Carlo simulation. Int J Infect Dis. 18:62–67. 2014.PubMed/NCBI View Article : Google Scholar
|
